Market closed

Intellia Therapeutics/$NTLA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Ticker

$NTLA
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

526
Website
www.intelliatx.com

NTLA Metrics

BasicAdvanced
$1B
-
-$5.44
1.81
-

$1B

1.81

$34.87

$9.65

2.5M

6.727

6.311

8.565

10.557

-27.81%

-52.23%

22.392

1.06

1.06

-2.657

-16.77%

1.73%

17.16%

17.14%

What the Analysts think about NTLA

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Intellia Therapeutics stock.

NTLA Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

NTLA Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

NTLA News

AllArticlesVideos
Lost Money on Intellia Therapeutics, Inc. (NTLA)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

Lost Money on Intellia Therapeutics, Inc. (NTLA)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

Accesswire·14 hours ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out

Accesswire·14 hours ago
Shareholder Rights Advocates at Levi & Korsinsky Investigate Intellia Therapeutics, Inc. (NTLA) Regarding Possible Securities Fraud Violations

Shareholder Rights Advocates at Levi & Korsinsky Investigate Intellia Therapeutics, Inc. (NTLA) Regarding Possible Securities Fraud Violations

Accesswire·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NTLA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Intellia Therapeutics stock?

Intellia Therapeutics (NTLA) has a market cap of $1B as of January 15, 2025.

What is the P/E ratio for Intellia Therapeutics stock?

The price to earnings (P/E) ratio for Intellia Therapeutics (NTLA) stock is 0 as of January 15, 2025.

Does Intellia Therapeutics stock pay dividends?

No, Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Intellia Therapeutics dividend payment date?

Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders.

What is the beta indicator for Intellia Therapeutics?

Intellia Therapeutics (NTLA) has a beta rating of 1.81. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.